Novel ADCs from Asia open new clinical opportunities
Phase I–II studies showcase the clinical potential of novel ADCs with enhanced targeting and/or payload strategies
Access to targeted treatments for patients with CUP is still an issue
Studies underline that a tumour-agnostic approach may help improve treatment options
Population diversity in cancer treatment – differences matter
Recognising diversity is essential to providing effective, well tolerated and accessible cancer care globally
177Lu-DOTATATE prolongs progression-free survival in previously treated advanced GEP-NETs
Impressive results from the Chinese LUMINET-1 phase III study confirm and extend previous findings in Western patients
A new claudin 18.2-targeting approach appears promising in gastric cancers
A triple combination investigated in a phase I trial adds to the growing therapeutic options directed at this emerging target
First-in-class p53 reactivator shows activity in advanced solid tumours
Initial results of a phase II trial with rezatapopt suggest real promise in an area that has eluded druggable targeting
Going beyond protocol is key for young people with cancer
For adolescents and young adults with cancer, individualised care that addresses their unique medical and psychosocial needs is essential to improving outcomes and quality of life
Bridging the interpretation gap in cancer genomics – the next frontier for ai in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
AI-powered three-dimensional tumour pathology
Computational models can overcome current limitations of 3D analysis of tumour samples
AI tool outperforms manual PD-L1 scoring in a study
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy